This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Indoleamine 2,3-dioxygenase 1 (IDO1)	<p><i>In vitro</i> studies identified an IDO1 inhibitor that could help treat cancer. In SAR studies and in IDO1-expressing human and murine cells, a lead phenyltriazole analog was identified as a selective, nanomolar inhibitor of IDO1. Planned studies include testing the compound in mice with murine mast cell tumors.</p> <p>iTeos Therapeutics S.A. has undisclosed IDO (INDO) inhibitors in preclinical development for cancer.</p> <p>1-Methyl-D-tryptophan (D-1MT), an IDO inhibitor from NewLink Genetics Corp., is in Phase Ib/II testing to treat solid tumors.</p> <p>INCB24360, an IDO inhibitor from Incyte Corp., is in Phase I testing to treat solid tumors.</p> <p>SciBX 5(23); doi:10.1038/scibx.2012.593 Published online June 7, 2012</p>	Patented by the Ludwig Institute for Cancer Research and the Swiss Institute of Bioinformatics; licensed to iTeos	<p>Röhrig, U.F. <i>et al. J. Med. Chem.</i>; published online May 22, 2012; doi:10.1021/jm300260v</p> <p>Contact: Olivier Michielin, Swiss Institute of Bioinformatics, Lausanne, Switzerland e-mail: olivier.michielin@isb-sib.ch</p> <p>Contact: Vincent Zoete, same affiliation as above e-mail: vincent.zoete@isb-sib.ch</p>